Document is current
Any future updates will be listed below
-
Authors
Bark, Lovisa
Larsson, Ing-Marie
Wallin, Ewa
Simrén, Joel
Zetterberg, Henrik
Lipcsey, Miklos
Frithiof, Robert
Rostami, Elham
Hultström, Michael
- License Information
-
More Information
Article History
Received: 13 August 2022
Accepted: 29 July 2023
First Online: 12 August 2023
Competing interests
: HZ has served at scientific advisory boards and/or as a consultant for Abbvie, Alector, ALZPath, Annexon, Apellis, Artery Therapeutics, AZTherapies, CogRx, Denali, Eisai, Nervgen, Novo Nordisk, Passage Bio, Pinteon Therapeutics, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures in symposia sponsored by Cellectricon, Fujirebio, Alzecure, Biogen, and Roche, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work). All the other authors declare they have no conflicts of interest.
